CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0020

Anadrol Oil

Filed under Injectable Oils. The bureau holds 122 laboratory returns for this compound from 43 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

43 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 4 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
Sangon BioCASE #VI-2026-0671 A 4 10.0 10.0 10.0 20 Jan 2026 4 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 3 10.0 9.9 10.0 11 Apr 2026 5 May 2026
PolyPeptide GroupCASE #VI-2026-0143 A 3 10.0 9.9 10.0 25 Feb 2026 27 Jul 2026
SinoPepCASE #VI-2026-0387 A 3 10.0 9.9 10.0 16 Mar 2026 18 Jul 2026
AsymchemCASE #VI-2026-0091 A 3 10.0 9.9 10.0 5 May 2026 6 Jul 2026
Kerui PeptidesCASE #VI-2026-0626 A 2 10.0 10.0 10.0 19 Jun 2026 4 Jul 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 2 10.0 10.0 10.0 17 Apr 2026 21 May 2026
Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 X 1 10.0 10.0 10.0 27 Feb 2025 27 Feb 2025
HomopeptideCASE #VI-2026-0760 A 4 9.9 9.9 10.0 24 May 2026 24 May 2026
QYAOBIOCASE #VI-2026-0861 A 4 9.9 9.9 10.0 28 Apr 2026 6 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 4 9.9 9.9 9.9 23 Mar 2026 22 Jun 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 4 9.9 9.9 9.9 6 May 2026 12 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 4 9.9 9.9 10.0 13 May 2026 20 Jun 2026
GenScript PeptidesCASE #VI-2026-0860 A 4 9.9 9.9 10.0 8 Dec 2025 9 Aug 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 9.9 9.9 10.0 12 Jan 2026 7 Jul 2026
WuXi TIDESCASE #VI-2026-0335 A 3 9.9 9.9 10.0 4 Jan 2026 20 Jun 2026
Sigma-AldrichCASE #VI-2026-0829 A 3 9.9 9.9 10.0 17 Feb 2026 20 Jun 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 9.9 9.9 10.0 7 Jun 2026 21 Jun 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 9.9 9.9 10.0 14 May 2026 4 Jun 2026
BachemCASE #VI-2026-0314 A 2 9.9 9.9 10.0 20 Dec 2025 11 May 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 10.0 19 Mar 2026 4 Jul 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 2 9.9 9.9 10.0 15 Jan 2026 4 Jun 2026
AmbioPharmCASE #VI-2026-0177 A 2 9.9 9.9 10.0 22 Apr 2026 19 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 7 8.9 7.8 9.9 23 May 2026 23 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 3 8.7 7.9 10.0 23 May 2026 23 May 2026
Precision Peptide CoCASE #VI-2026-0559 X 1 8.6 8.6 8.6 8 Jul 2025 8 Jul 2025
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 6 8.1 6.9 9.4 23 May 2026 23 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 7 7.8 7.1 8.8 24 May 2026 24 May 2026
HealthTide BiotechCASE #VI-2026-0955 X 1 7.8 7.8 7.8 13 Feb 2025 13 Feb 2025
Glbiochem (Shanghai)CASE #VI-2026-0704 A 4 7.5 6.5 8.4 24 May 2026 24 May 2026
Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 X 1 6.9 6.9 6.9 7 May 2025 7 May 2025
PeptiLab ResearchCASE #VI-2026-0267 X 1 6.9 6.9 6.9 13 Feb 2025 13 Feb 2025
Henan Sahe PeptideCASE #VI-2026-0894 X 1 6.7 6.7 6.7 6 May 2025 6 May 2025
LipeptidesCASE #VI-2026-0863 X 1 6.4 6.4 6.4 13 Jun 2025 13 Jun 2025
UtherCASE #VI-2026-0902 X 4 6.2 4.8 7.6 3 Jun 2025 17 May 2026
ZhuoYan labCASE #VI-2026-0902 X 3 6.2 6.1 6.2 21 May 2025 23 May 2026
Limitless Life NootropicsCASE #VI-2026-0980 X 2 5.4 3.8 7.0 8 Jul 2025 26 Jan 2026
NexaphCASE #VI-2026-0944 X 5 5.0 3.5 7.4 25 Apr 2025 24 May 2026
Coastal PeptidesCASE #VI-2026-0958 X 1 4.3 4.3 4.3 13 Feb 2025 13 Feb 2025
Haikou Mingheng TechnologyCASE #VI-2026-0250 X 1 3.5 3.5 3.5 25 Apr 2025 25 Apr 2025
Explicit SarmsCASE #VI-2026-0017 X 1 0.7 0.7 0.7 3 Jul 2025 3 Jul 2025
HK Fat CatCASE #VI-2026-0376 X 1 0.4 0.4 0.4 25 Apr 2025 25 Apr 2025

Open any subject to view the batch-level evidence for Anadrol Oil alone.